Lin Ruihe, Cai Jingli, Kostuk Eric W, Rosenwasser Robert, Iacovitti Lorraine
The Joseph and Marie Field Cerebrovascular Research Laboratory at Jefferson, Vickie & Jack Farber Institute for Neurosciences, Department of Neuroscience, Sidney Kimmel Medical College, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA, 19107, USA.
The Joseph and Marie Field Cerebrovascular Research Laboratory at Jefferson, Vickie & Jack Farber Institute for Neuroscience, Department of Neurological Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
J Neuroinflammation. 2016 Oct 13;13(1):269. doi: 10.1186/s12974-016-0733-1.
Dimethyl fumarate (DMF), working via its metabolite monomethylfumarate (MMF), acts as a potent antioxidant and immunomodulator in animal models of neurologic disease and in patients with multiple sclerosis. These properties and their translational potential led us to investigate whether DMF/MMF could also protect at-risk and/or dying neurons in models of ischemic stroke in vitro and in vivo. Although the antioxidant effects have been partially addressed, the benefits of DMF immunomodulation after ischemic stroke still need to be explored.
In vitro neuronal culture with oxygen-glucose deprivation and rats with middle cerebral artery occlusion were subjected to DMF/MMF treatment. Live/dead cell counting and LDH assay, as well as behavioral deficits, plasma cytokine assay, western blots, real-time PCR (Q-PCR) and immunofluorescence staining, were used to evaluate the mechanisms and neurological outcomes.
We found that MMF significantly rescued cortical neurons from oxygen-glucose deprivation (OGD) in culture and suppressed pro-inflammatory cytokines produced by primary mixed neuron/glia cultures subjected to OGD. In rats, DMF treatment significantly decreased infarction volume by nearly 40 % and significantly improved neurobehavioral deficits after middle cerebral artery occlusion (MCAO). In the acute early phase (72 h after MCAO), DMF induced the expression of transcription factor Nrf2 and its downstream mediator HO-1, important for the protection of infarcted cells against oxidative stress. In addition to its antioxidant role, DMF also acted as a potent immunomodulator, reducing the infiltration of neutrophils and T cells and the number of activated microglia/macrophages in the infarct region by more than 50 % by 7-14 days after MCAO. Concomitantly, the levels of potentially harmful pro-inflammatory cytokines were greatly reduced in the plasma and brain and in OGD neuron/glia cultures.
We conclude that DMF is neuroprotective in experimental stroke because of its potent immunomodulatory and antioxidant effects and thus may be useful as a novel therapeutic agent to treat stroke in patients.
富马酸二甲酯(DMF)通过其代谢产物单甲基富马酸(MMF)发挥作用,在神经疾病动物模型和多发性硬化症患者中作为一种有效的抗氧化剂和免疫调节剂。这些特性及其转化潜力促使我们研究DMF/MMF在体外和体内缺血性中风模型中是否也能保护处于危险中的和/或即将死亡的神经元。尽管抗氧化作用已得到部分研究,但缺血性中风后DMF免疫调节的益处仍有待探索。
对氧糖剥夺的体外神经元培养物和大脑中动脉闭塞的大鼠进行DMF/MMF治疗。使用活/死细胞计数和乳酸脱氢酶(LDH)测定,以及行为缺陷、血浆细胞因子测定、蛋白质免疫印迹、实时聚合酶链反应(Q-PCR)和免疫荧光染色来评估其作用机制和神经学结果。
我们发现MMF能显著挽救培养物中氧糖剥夺(OGD)后的皮质神经元,并抑制OGD处理的原代混合神经元/神经胶质细胞培养物产生的促炎细胞因子。在大鼠中,DMF治疗使大脑中动脉闭塞(MCAO)后的梗死体积显著减少近40%,并显著改善神经行为缺陷。在急性早期(MCAO后72小时),DMF诱导转录因子Nrf2及其下游介质HO-1的表达,这对于保护梗死细胞免受氧化应激至关重要。除了其抗氧化作用外,DMF还是一种有效的免疫调节剂,在MCAO后7至14天,使梗死区域中性粒细胞和T细胞的浸润以及活化的小胶质细胞/巨噬细胞数量减少超过50%。同时,血浆、大脑和OGD神经元/神经胶质细胞培养物中潜在有害的促炎细胞因子水平大大降低。
我们得出结论,DMF因其强大的免疫调节和抗氧化作用在实验性中风中具有神经保护作用,因此可能作为一种新型治疗药物用于治疗中风患者。